Sunshine Pharmaceutical (1530.HK) climbed 3.6% to HK$17.10 in Hong Kong trading on Friday.

The move followed the company's first-half 2026 results. Revenue rose 3.9% to RMB 4.53 billion, while net profit fell 15.6% to RMB 1.15 billion. The company noted progress on its innovation pipeline, with biosimilar Yisaipu and a new indication winning regulatory approval. Its R&D staff expanded to roughly 840, and management said it will continue commercialization and drug-development partnerships in the second half.